Efficacy of topical 5-Fluorouracil in the management of ocular surface squamous neoplasia: a study of 101 eyes.
Humans
Fluorouracil
/ administration & dosage
Retrospective Studies
Aged
Male
Middle Aged
Female
Adult
Aged, 80 and over
Adolescent
Antimetabolites, Antineoplastic
/ administration & dosage
Young Adult
Ophthalmic Solutions
/ administration & dosage
Child
Treatment Outcome
Carcinoma, Squamous Cell
/ drug therapy
Administration, Topical
Eye Neoplasms
/ drug therapy
Conjunctival Neoplasms
/ drug therapy
Corneal Diseases
/ drug therapy
Follow-Up Studies
5-fluorouracil
Conjunctiva
Eye
OSSN
Ocular surface squamous neoplasia
Tumor
Journal
International ophthalmology
ISSN: 1573-2630
Titre abrégé: Int Ophthalmol
Pays: Netherlands
ID NLM: 7904294
Informations de publication
Date de publication:
22 Jun 2024
22 Jun 2024
Historique:
received:
10
04
2024
accepted:
15
06
2024
medline:
22
6
2024
pubmed:
22
6
2024
entrez:
22
6
2024
Statut:
epublish
Résumé
To study the efficacy and side-effect profile of topical 5-Fluorouracil (5-FU) in the treatment of ocular surface squamous neoplasia (OSSN). Retrospective study of 101 eyes of 100 patients treated with 5-FU with one week on and 3 weeks off regimen. Of the 100 patients (101 eyes), the mean age at diagnosis of OSSN was 49 (median, 52 years; range, 11-87 years). History of prior intervention was noted in 6 (6%) eyes. Tumor epicenter included bulbar conjunctiva (n = 54; 53%), limbus (n = 27; 27%), and cornea (n = 20;20%). Mean number of cycles of topical 5-FU administered was 3 (median, 3; range, 1-8). Complete tumor regression was achieved with topical 5-FU in 89 (88%) eyes with a mean number of 2 cycles (median, 2; range, 1-6) of 5-FU. The remaining 12 (12%) lesions underwent additional treatment including excisional biopsy (n = 7), extended enucleation (n = 3), and topical Interferon alpha 2b (n = 2) for complete tumor control. Over a mean follow-up period of 6 months (median, 5 months; range, 1-36 months) following treatment, tumor recurrence was noted in 2 (2%) patients, and side-effects were noted in 7 (7%) eyes including conjunctival hyperemia (n = 1), punctal stenosis (n = 1), sterile keratitis (n = 4), and limbal stem cell deficiency (n = 1). Topical 5-FU is an effective non-invasive therapy for OSSN with a minimal side-effect profile.
Identifiants
pubmed: 38907750
doi: 10.1007/s10792-024-03182-x
pii: 10.1007/s10792-024-03182-x
doi:
Substances chimiques
Fluorouracil
U3P01618RT
Antimetabolites, Antineoplastic
0
Ophthalmic Solutions
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
251Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Nature B.V.
Références
Shields CL, Shields JA (2004) Tumours of the conjunctiva and cornea. Surv Ophthalmol 49:3–24
doi: 10.1016/j.survophthal.2003.10.008
pubmed: 14711437
Ateenyi-Agaba C (1995) Conjunctival squamous-cell carcinoma associated with HIV infection in Kampala. Uganda The Lancet 345:695–696
doi: 10.1016/S0140-6736(95)90870-6
Newton R, Ferlay J, Reeves G, Beral V, Parkin DM (1996) Effect of ambient solar ultraviolet radiation on incidence of squamous-cell carcinoma of the eye. The Lancet 347:1450–1451
doi: 10.1016/S0140-6736(96)91685-2
Kaliki S, Vempuluru VS, Ghose N, Gunda S, Vithalani NM, Sultana S et al (2022) Ocular surface squamous neoplasia in India: a study of 438 patients. Int Ophthalmol 42(6):1915–1926
doi: 10.1007/s10792-021-02189-y
pubmed: 35094225
Dandala PP, Malladi P, Kavitha (2015) Ocular surface squamous neoplasia (OSSN) a retrospective study. J Clin Diagn Res 9(11):10–13
Shields JA, Shields CL, De Potter P (1997) Surgical management of conjunctival tumors: the 1994 Lynn B McMahan Lecture. Archives ophthalmol 115(6):808–815
doi: 10.1001/archopht.1997.01100150810025
Tabin G, Levin S, Snibson G, Loughnan M, Taylor H (1997) Late recurrences and the necessity for long-term follow-up in corneal and conjunctival intraepithelial neoplasia. Ophthalmology 104(3):485–492
doi: 10.1016/S0161-6420(97)30287-5
pubmed: 9082277
Cicinelli MV, Marchese A, Bandello F, Modorati G (2018) Clinical management of ocular surface squamous neoplasia: a review of the current evidence. Ophthalmol Ther 7(2):247–262
doi: 10.1007/s40123-018-0140-z
pubmed: 30030703
pmcid: 6258579
Adler E, Turner JR, Stone DU (2013) Ocular surface squamous neoplasia: a survey of changes in the standard of care from 2003 to 2012. Cornea 32(12):1558–1561
doi: 10.1097/ICO.0b013e3182a6ea6c
pubmed: 24145630
Kusumesh R, Ambastha A, Sinha B, Kumar R (2015) Topical interferon alpha-2b as a single therapy for primary ocular surface squamous neoplasia. Asia Pac J Ophthalmol (Phila) 4(5):279–282
doi: 10.1097/APO.0000000000000104
pubmed: 26176194
Daniell M, Maini R, Tole D (2002) Use of mitomycin C in the treatment of corneal conjunctival intraepithelial neoplasia. Clin Exp Ophthalmol 30(2):94–98
doi: 10.1046/j.1442-6404.2002.00497.x
pubmed: 11886411
Tsatsos M, Karp CL (2014) Modern management of ocular surface squamous neoplasia. Expert Rev Ophthalmol 8(3):287–295
doi: 10.1586/eop.13.16
Khong JJ, Muecke J (2006) Complications of mitomycin C therapy in 100 eyes with ocular surface neoplasia. Br J Ophthalmol 90(7):819–822
doi: 10.1136/bjo.2005.086850
pubmed: 16672325
pmcid: 1857172
Al Bayyat G, Arreaza-Kaufman D, Venkateswaran N, Galor A, Karp CL (2019) Update on pharmacotherapy for ocular surface squamous neoplasia. Eye Vis (Lond) 12(6):24. https://doi.org/10.1186/s40662-019-0150-5
doi: 10.1186/s40662-019-0150-5
Longley D, Harkin D, Johnston P (2003) 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3:330–338
doi: 10.1038/nrc1074
pubmed: 12724731
Abraham SM, Selva D, Casson R, Leibovitch I (2007) The clinical applications in fluorouracil in ophthalmic practice. Drugs 67:237–255
doi: 10.2165/00003495-200767020-00005
pubmed: 17284086
Sayed-Ahmed IO, Palioura S, Galor A, Karp CL (2017) Diagnosis and medical management of ocular surface squamous neoplasia. Expert Rev Ophthalmol 12(1):11–19
doi: 10.1080/17469899.2017.1263567
pubmed: 28184236
Nutt RJ, Clements JL, Dean WH (2014) Ocular surface squamous neoplasia in HIV-positive and HIV-negative patients and response to 5-fluorouracil in Angola. Clin Ophthalmol 8:2435–2440
doi: 10.2147/OPTH.S70459
pubmed: 25506205
pmcid: 4259503
Midena E, Angeli CD, Valenti M, de Belvis V, Boccato P (2000) Treatment of conjunctival squamous cell carcinoma with topical 5-fluorouracil. Br J Ophthalmol 84:268–272
doi: 10.1136/bjo.84.3.268
pubmed: 10684836
pmcid: 1723406
Wylegala A, Sripawadkul W, Zein M, Alvarez OP, Al Bayyat G, Galor A et al (2023) Topical 1% 5-fluorouracil eye drops as primary treatment for ocular surface squamous neoplasia: Long-term follow-up study. Ocul Surf 27:67–74
doi: 10.1016/j.jtos.2022.12.002
pubmed: 36476665
Geng W, Wang JS, Shi BJ, Xie HT, Zhang MC (2022) Topical chemotherapy for treating ocular surface squamous neoplasia with a combination of interferon α-2b and 5-Fluorouracil. Ophthalmol Therapy 11(4):1563–1576
doi: 10.1007/s40123-022-00535-6
Parrozzani R, Frizziero L, Trainiti S, Testi I, Miglionico G, Pilotto E et al (2017) Topical 1% 5-fluoruracil as a sole treatment of corneoconjunctival ocular surface squamous neoplasia: long-term study. Br J Ophthalmol 101:1094–1099
doi: 10.1136/bjophthalmol-2016-309219
pubmed: 27941046
Frucht-Pery J, Rozenman Y (1994) Mitomycin C therapy for corneal intraepithelial neoplasia. Am J Ophthalmol 117:164–168
doi: 10.1016/S0002-9394(14)73072-7
pubmed: 8116744
Papandroudis AA, Dimitrakos SA, Stangos NT (2002) Mitomycin C therapy for conjunctival-corneal intraepithelial neoplasia. Cornea 21:715–717
doi: 10.1097/00003226-200210000-00017
pubmed: 12352093
Tseng SH, Tsai YY, Chen FK (1997) Successful treatment of recurrent corneal intraepithelial neoplasia with topical mitomycin C. Cornea 16:595–597
doi: 10.1097/00003226-199709000-00020
pubmed: 9294697
Sturges A, Butt AL, Lai JE, Chodosh J (2008) Topical interferon or surgical excision for the management of primary ocular surface squamous neoplasia. Ophthalmology 115:1297–1302
doi: 10.1016/j.ophtha.2008.01.006
pubmed: 18294690
Zarei-Ghanavati S, Alizadeh R, Deng SX (2014) Topical interferon alpha-2b for treatment of noninvasive ocular surface squamous neoplasia with 360 degrees limbal involvement. J Ophthalmic Vis Res 9:423–426
doi: 10.4103/2008-322X.150811
pubmed: 25709765
pmcid: 4329700
Yeatts RP, Engelbrecht NE, Curry CD, Ford JG, Walter KA (2000) 5-Fluorouracil for the treatment of intraepithelial neoplasia of the conjunctiva and cornea. Ophthalmology 107:2190–2195
doi: 10.1016/S0161-6420(00)00389-4
pubmed: 11097594
Parrozzani R, Lazzarini D, Alemany-Rubio E, Urban F, Midena E (2011) Topical 1% 5-fluorouracil in ocular surface squamous neoplasia: a long-term safety study. Br J Ophthalmol 95:355–359
doi: 10.1136/bjo.2010.183244
pubmed: 20693564
Joag MG, Sise A, Murillo JC, Sayed-Ahmed IO, Wong JR, Mercado C et al (2016) Topical 5-Fluorouracil 1% as primary treatment for ocular surface squamous neoplasia. Ophthalmology 123(7):1442–1448
doi: 10.1016/j.ophtha.2016.02.034
pubmed: 27030104